Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  • STATUS
    Not Recruiting
  • participants needed
    175
  • sponsor
    Novartis Pharmaceuticals
Updated on 17 November 2021
Novartis Investigative Site (2.5 mi away) Contact
remission
lipase
potassium
leukemia
nilotinib

Summary

The main purpose of the study is to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment

Details
Condition Chronic myeloid leukemia
Treatment Nilotinib followed by treatment-free
Clinical Study IdentifierNCT01784068
SponsorNovartis Pharmaceuticals
Last Modified on17 November 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note